Tag: Europe
-

Virtual Drug Discovery Incubator Launched for Univ. Labs
Life science investors and a drug discovery company started a remote business incubator service to discover and develop early therapy candidates from academic research.
-

Industry, Univ. Labs Partner on Covid-19 Therapy
Researchers from industry and academic labs are developing a synthetic antibody that in lab tests shows promise as both a Covid-19 therapy and vaccine.
-

Fix Discovered for Gene Therapy Virus Delivery
Researchers in France and the U.S. discovered a bacterial enzyme that blocks immune reactions to otherwise benign viruses that deliver gene therapies.
-

Drug Maker Licenses Low-Dose Vaccine Patch
The pharmaceutical company Merck is licensing a microneedle patch device that delivers vaccines with a small fraction of the dose normally needed by syringes.
-

Merck Inks Three Covid-19 Vaccine, Therapy Deals
Drug maker Merck today gained a new acquisition, along with collaboration and licensing deals, for vaccines and a therapy for Covid-19 infections.
-

Depression Therapy Licensed for Online Distribution
A therapy program for depression designed to reduce spirals of repeated negative thinking is licensed to a digital mental health company for online use.
-

Antibody Neutralizes Covid-19, SARS Viruses
An academic-industry team discovered that an antibody produced during the 2003 SARS outbreak can neutralize similar viruses causing Covid-19 infections.
-

Covid-19 Lung Disease Trial Adds Treatments
A clinical trial testing treatments for lung damage in severe Covid-19 cases is adding the anti-viral drug remdesivir and convalescent plasma to its protocol.
-

Int’l Group Backs Novavax Covid-19 Vaccine
A global consortium is funding a biotechnology company’s clinical trials and manufacturing plans for a vaccine protecting against Covid-19 viruses.
-

Stem Cell Therapy Licensed for Genetic Eye Disease
A biotechnology company is licensing its stem cell treatments for retinitis pigmentosa, an inherited eye disease, in a deal valued at $252 million.